Neurotech founder Adrian Trevisan (left) with chief executive Wolfgang Storf.

Neurotech makes solid ASX debut

A neuroscience-focused business that has been backed by the Perth-based Trevisan family has made a solid debut on the ASX after completing a $7 million initial public offering led by Azure Capital.


(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Total Shareholder Return as at 29/06/18

1 year TSR5 year TSR
69thBotanix Pharmaceuticals164%106%
144thUltima United90%5%
679thNeurotech International-36%0%
722 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Share Transactions

$113k Issued
$66k Issued
Total value as at the date of the transaction
Source: Morningstar


184th↑Neurotech International$104k
207th↓Ultima United$2k
210th↓Mission NewEnergy$5
211th↓Botanix Pharmaceuticals$0
239 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer